Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis

NCT03974100 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

527

Enrollment

INDUSTRY

Sponsor class

Conditions

Postmenopausal Women With Osteoporosis

Interventions

BIOLOGICAL: GP2411
BIOLOGICAL: EU-Prolia (EU-authorized Prolia®)

Sponsor

Sandoz

Collaborators

[object Object]